PAVMED INC. (NASDAQ:PAVM) Files An 8-K Regulation FD Disclosure
Item 7.01 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any disclosure document of the Company, except as shall be expressly set forth by specific reference in such document.
(d) Exhibits:
| Exhibit No. | Description |
| 99.1 | Press release. |
PAVmed Inc. Exhibit
EX-99.1 2 ex99-1.htm Exhibit 99.1 PAVmed Subsidiary Lucid Diagnostics Partners with Fred Hutchinson Cancer Research Center to Evaluate Barrett’s Esophagus (BE) Progression Biomarkers Using EsoCheck™ Lucid secures exclusive option to license biomarker technology to detect progression from nondysplastic to dysplastic BE using EsoCheck to allow curative ablation before deadly esophageal cancer develops NEW YORK,…
To view the full exhibit click here